Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics PLC is positioned to benefit from the increasing prevalence of CAR-T therapy in the UK, which is expected to drive significant revenue growth in 2026, with estimates reaching $167 million, marking a 220% year-over-year increase. Additionally, the anticipated revenue for Aucatzyl between $120 million and $135 million reflects a robust 60-80% increase compared to the previous year, supported by the expansion of the ATC network to over 80 locations. Furthermore, the company's improvement in sales margins as operations scale up is forecasted to contribute positively to overall financial performance, suggesting a favorable outlook for the business.

Autolus Therapeutics has experienced a significant decline in its stock value, down approximately 48% since July 2025, which contrasts sharply with a 40% increase in the sector, raising concerns regarding its stagnating revenue growth, particularly in its initial product launch of Aucatzyl. The company faces manufacturing constraints due to a made-to-order product model, leading to insufficient inventory and consequently, flat revenue performance in the latter half of 2025. Additionally, the company carries substantial risk factors, including potential safety signals, lower-than-expected efficacy in clinical programs, and the necessity for an estimated $1.0 billion in capital through 2038, all contributing to a negative outlook for its financial stability and growth prospects.